Avadel Pharmaceuticals plc (AVDL)
Avadel Pharmaceuticals plc operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Dublin, IE. The stock last traded at $21.64, up 0.00% on the session, giving a market capitalisation of $2.12B. On trailing twelve-month figures it carries a trailing P/E of 431.08, a net margin of 2.4%. Its beta of 1.31 implies it has historically moved more than the broad market.
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.
Avadel Pharmaceuticals plc is most often compared with the following Healthcare names: